AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Bank of Montreal (BMO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

101.06

0.59 (0.59%)

At close: Feb 14, 2025, 3:59 PM

undefined% (undefined)

Bid	90
Market Cap	73.74B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	6.66
PE Ratio (ttm)	15.17
Forward PE	n/a
Analyst	Hold

Ask	104
Volume	247,495
Avg. Volume (20D)	672,425
Open	100.77
Previous Close	100.47
Day's Range	100.69 - 101.58
52-Week Range	76.98 - 104.63
Beta	undefined

About BMO

Bank of Montreal provides diversified financial services primarily in North America. The company's personal banking products and services include checking and savings accounts, credit cards, mortgages, and financial and investment advice services; and commercial banking products and services comprise business deposit accounts, commercial credit cards, business loans and commercial mortgages, cash management solutions, foreign exchange, specialize...

[Show more]

Industry Banks - Diversified

Sector Financial Services

IPO Date Oct 27, 1994

Employees 55,767

Stock Exchange NYSE

Ticker Symbol BMO

Website https://www.bmo.com

Analyst Forecast

According to 5 analyst ratings, the average rating for BMO stock is "Hold." The 12-month stock price forecast is $120.5, which is an increase of 19.23% from the latest price.

Buy 40.00%

Hold 60.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago

+3.83%

BMO shares are trading higher after RBC Capital ra... Unlock content with Pro Subscription

5 months ago

-6.16%

Bank of Montreal shares are trading lower after the company reported worse-than-expected Q3 financial results.

News

3 days ago · businesswire.com

Royal Gold Presenting at BMO's 34th Global Metals, Mining and Critical Minerals Conference

DENVER--(BUSINESS WIRE)--Royal Gold Presenting at BMO's 34th Global Metals, Mining and Critical Minerals Conference.

3 weeks ago · fool.com

3 Unstoppable Dividend Stocks That Can Be Pillars to Build Your Portfolio Around

If you're a new investor, want some recurring dividend income, or just want some top stocks to build your portfolio around, it's important to focus on businesses with strong fundamentals and room to g...

4 weeks ago · seekingalpha.com

Bank of Montreal: Strengths And Risks That Need Consideration

BMO is rated a 'buy' for long-term value investors due to its strong capital position, reliable dividends, and operational improvements despite some financial challenges. BMO's CET1 ratio of 13.6% and...

1 month ago · reuters.com

London Metal Exchange approves Bank of Montreal as member

The London Metal Exchange (LME) has approved Bank of Montreal (BMO) as a category 2 member, the exchange said on Tuesday.

1 month ago · kitco.com

Gold's role as a dynamic hedge will drive prices above $2,850 this year - BMO Capital Markets

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include cover...

1 month ago · youtube.com

Under Armour is an under-appreciated retail stock, says BMO's Simeon Siegel

Simeon Siegel, BMO Capital Markets analyst, joins 'Squawk on the Street' to discuss the potential risks for the retail sector.

1 month ago · youtube.com

Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman

Evan Siegerman, BMO biotech analyst, joins 'Power Lunch' to discuss the big winners in the pharmaceutical space in 2025.

1 month ago · youtube.com

BMO's Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.

1 month ago · https://thefly.com

Pfizer's 2025 guidance positions company for EPS expansion, says BMO

BMO Capital reiterated an Outperform rating and $36 price target on Pfizer, saying that 2025 guidance succeeds in meeting the majority of the firm's expectations outlined in its preview, positioning t...

1 month ago · kitco.com

Gold is the brightest star in 2025, silver remains in second place - BMO Capital Markets

Load More News